Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulindac

FDA-approved product (tablet, oral), marketed as Clinoril, Sulindac.

Registered studies
40
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulindac
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Osteoarthritis
  • Rheumatic disease
  • Rheumatoid arthritis
  • Spondylitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Acetic acid derivatives and related substances
FDA pharmacologic class
Nonsteroidal Anti-inflammatory Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA29.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

40registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sulindac in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulindac with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses

    NCT06693362 · start 2025-01-20

    Registered record
    Registry ID
    NCT06693362
    Conditions
    Severe Viral Pneumonia(Not Include COVID-19)
    Interventions
    Placebo; Drug therapy; Standard Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-01-20
    Completion
    2028-06-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Viral Pneumonia(Not Include COVID-19)
    InterventionPlacebo; Drug therapy; Standard Treatment
    PhasePhase 1
    Registry statusRecruiting

  • Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40

    NCT04823052 · start 2022-05-25

    Registered record
    Registry ID
    NCT04823052
    Conditions
    Fragile X Syndrome
    Interventions
    Sulindac (HLX-0201), dose strength 1; Sulindac (HLX-0201), dose strength 2; Placebo; Gaboxadol (HLX-0206)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2022-05-25
    Completion
    2022-10-19
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFragile X Syndrome
    InterventionSulindac (HLX-0201), dose strength 1; Sulindac (HLX-0201), dose strength 2; Placebo; Gaboxadol (HLX-0206)
    PhasePhase 2
    Registry statusWithdrawn

  • Dual vs. Single-Antibiotic Impregnated Cement in Hemiarthroplasty for Femoral Neck Fracture

    NCT05164081 · start 2022-01-01

    Registered record
    Registry ID
    NCT05164081
    Conditions
    Femoral Neck Fractures; Prosthetic Infection
    Interventions
    antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).; antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-01-01
    Completion
    2027-01-31
    Enrolment
    7,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFemoral Neck Fractures; Prosthetic Infection
    Interventionantibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).; antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
    PhasePhase 3
    Registry statusActive not recruiting

  • Sulindac and Breast Density in Women at Risk of Developing Breast Cancer

    NCT04542135 · start 2020-11-20

    Registered record
    Registry ID
    NCT04542135
    Conditions
    Breast Cancer
    Interventions
    Sulindac Pill; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-11-20
    Completion
    2025-05-19
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionSulindac Pill; Placebo
    PhasePhase 2
    Registry statusCompleted

  • The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

    NCT04207944 · start 2020-07-10

    Registered record
    Registry ID
    NCT04207944
    Conditions
    IPMN; IPMN, Pancreatic
    Interventions
    Sulindac 400 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-07-10
    Completion
    2026-10-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIPMN; IPMN, Pancreatic
    InterventionSulindac 400 MG; Placebo
    PhasePhase 2
    Registry statusActive not recruiting

  • Urinary Biomarker Study With Sulindac and Difluoromethylornithine

    NCT01636128 · start 2014-03

    Registered record
    Registry ID
    NCT01636128
    Conditions
    Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms
    Interventions
    difluoromethylornithine; Sulindac
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2014-03
    Completion
    2016-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFocus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms
    Interventiondifluoromethylornithine; Sulindac
    PhasePhase 2
    Registry statusWithdrawn

  • Sulindac for Patients With AML

    NCT01843179 · start 2014-01

    Registered record
    Registry ID
    NCT01843179
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Cytarabine; Sulindac
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2014-01
    Completion
    2014-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionCytarabine; Sulindac
    PhasePhase 2
    Registry statusWithdrawn

  • Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

    NCT01483144 · start 2013-10

    Registered record
    Registry ID
    NCT01483144
    Conditions
    Familial Adenomatous Polyposis
    Interventions
    Eflornithine; Eflornithine Placebo; Sulindac 150 MG; Sulindac placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-10
    Completion
    2019-03
    Enrolment
    171

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFamilial Adenomatous Polyposis
    InterventionEflornithine; Eflornithine Placebo; Sulindac 150 MG; Sulindac placebo
    PhasePhase 3
    Registry statusCompleted

  • S0820, Adenoma and Second Primary Prevention Trial

    NCT01349881 · start 2013-08-23

    Registered record
    Registry ID
    NCT01349881
    Conditions
    Colorectal Neoplasms
    Interventions
    Eflornithine placebo & sulindac placebo; eflornithine & sulindac placebo; Eflornithine placebo & sulindac; Eflornithine plus sulindac
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2013-08-23
    Completion
    2032-02-01
    Enrolment
    354

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Neoplasms
    InterventionEflornithine placebo & sulindac placebo; eflornithine & sulindac placebo; Eflornithine placebo & sulindac; Eflornithine plus sulindac
    PhasePhase 3
    Registry statusActive not recruiting

  • Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer

    NCT01856322 · start 2013-04

    Registered record
    Registry ID
    NCT01856322
    Conditions
    Colorectal Cancer; Liver Metastasis; Colorectal Adenocarcinoma
    Interventions
    Sulindac; Placebo; Validate assays and shipping methods
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-04
    Completion
    2015-01
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Liver Metastasis; Colorectal Adenocarcinoma
    InterventionSulindac; Placebo; Validate assays and shipping methods
    PhasePhase 2
    Registry statusTerminated

  • NSAID Effects on Clinical and Imaging Breast Biomarkers

    NCT01761877 · start 2012-12

    Registered record
    Registry ID
    NCT01761877
    Conditions
    Inflammation; Cancer; Pain; Hypertension
    Interventions
    Sulindac
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12
    Completion
    2019-03-11
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation; Cancer; Pain; Hypertension
    InterventionSulindac
    PhasePhase 2
    Registry statusCompleted

  • A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

    NCT01245816 · start 2011-03

    Registered record
    Registry ID
    NCT01245816
    Conditions
    Familial Adenomatous Polyposis
    Interventions
    Eflornithine plus Sulindac; Eflornithine plus Placebo; Sulindac plus Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2011-03
    Completion
    2013-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFamilial Adenomatous Polyposis
    InterventionEflornithine plus Sulindac; Eflornithine plus Placebo; Sulindac plus Placebo
    PhasePhase 3
    Registry statusWithdrawn

  • A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

    NCT01187901 · start 2010-04

    Registered record
    Registry ID
    NCT01187901
    Conditions
    Adenomatous Polyposis Coli
    Interventions
    Erlotinib; Sulindac; Placebo A; Placebo B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-04
    Completion
    2014-07
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenomatous Polyposis Coli
    InterventionErlotinib; Sulindac; Placebo A; Placebo B
    PhasePhase 2
    Registry statusCompleted

  • Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

    NCT00841204 · start 2009-02

    Registered record
    Registry ID
    NCT00841204
    Conditions
    Precancerous Condition
    Interventions
    sulindac; placebo; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-02
    Completion
    2011-02
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrecancerous Condition
    Interventionsulindac; placebo; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans

    NCT00275756 · start 2008-09

    Registered record
    Registry ID
    NCT00275756
    Conditions
    Glaucoma
    Interventions
    Timolol (drug); dorzolamide (drug); brimonidine (drug); Laser Doppler flowmetry; Goldmann applanation tonometer; Suction cup method
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2008-09
    Completion
    2014-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionTimolol (drug); dorzolamide (drug); brimonidine (drug); Laser Doppler flowmetry +2 more
    PhaseNot applicable
    Registry statusWithdrawn